DAICHIRONA
LIVE

Serial Number

79337785

Owner

DAIICHI SANKYO COMPANY, LIMITED

Filing Date

Jan 19, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DAICHIRONA Trademark

Serial Number: 79337785 • Registration: 6982621

DAICHIRONA is a trademark filed by DAIICHI SANKYO COMPANY, LIMITED on January 19, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

DAIICHI SANKYO COMPANY, LIMITED (329 trademarks)

3-5-1, NIHONBASHI HONCHO, CHUO-KU
TOKYO 103-8426 , JP

Entity Type: 03

Trademark Details

Filing Date

January 19, 2022

Registration Date

February 21, 2023

Published for Opposition

December 6, 2022

Goods & Services

Pharmaceutical preparations for the treatment and prevention of cancer, oncological diseases, leukemia, musculoskeletal disorders, muscular dystrophy, pseudoxanthoma, dermatological disorders, allergy, cardiovascular diseases, kidney diseases, fibrodysplasia ossificans progressiva; vaccines for human use

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Apr 2, 2026 NREP
NOTIFICATION PROCESSED BY IB
Apr 30, 2023 GPNX
FINAL DISPOSITION NOTICE SENT TO IB
Apr 6, 2023 FICS
FINAL DISPOSITION PROCESSED
Apr 5, 2023 FIMP
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Mar 23, 2023 GPAR
REGISTERED-PRINCIPAL REGISTER
Feb 21, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Dec 13, 2022 GPNX
PUBLISHED FOR OPPOSITION
Dec 6, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 23, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 23, 2022 OP2R
NOTICE OF PUBLICATION
Nov 16, 2022 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 31, 2022 CNSA
ASSIGNED TO EXAMINER
Oct 28, 2022 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Jul 3, 2022 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Jun 4, 2022 NREP
APPLICATION FILING RECEIPT MAILED
Apr 26, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 21, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Apr 15, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 7, 2022 REPR